Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Net Margin (2017 - 2025)

Neurocrine Biosciences' Net Margin history spans 15 years, with the latest figure at 19.08% for Q4 2025.

  • For Q4 2025, Net Margin rose 266.0% year-over-year to 19.08%; the TTM value through Dec 2025 reached 16.73%, up 224.0%, while the annual FY2025 figure was 16.73%, 224.0% up from the prior year.
  • Net Margin reached 19.08% in Q4 2025 per NBIX's latest filing, down from 26.36% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 110.61% in Q4 2021 to a low of 84.5% in Q2 2022.
  • Average Net Margin over 5 years is 13.65%, with a median of 16.03% recorded in 2025.
  • Peak YoY movement for Net Margin: crashed -9914bps in 2022, then skyrocketed 10560bps in 2023.
  • A 5-year view of Net Margin shows it stood at 110.61% in 2021, then tumbled by -80bps to 21.6% in 2022, then skyrocketed by 33bps to 28.67% in 2023, then plummeted by -43bps to 16.43% in 2024, then increased by 16bps to 19.08% in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Net Margin are 19.08% (Q4 2025), 26.36% (Q3 2025), and 15.64% (Q2 2025).